1097210-25-7

Basic information

• Product Name: (S)-4-(2-bromo-1-hydroxyethyl)benzonitrile
• Synonyms: (S)-4-(2-bromo-1-hydroxyethyl)benzonitrile
• CAS NO: 1097210-25-7
• Molecular Weight: 226.073
• Mol File: 1097210-25-7.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: (S)-4-(2-bromo-1-hydroxyethyl)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-(2-bromo-1-hydroxyethyl)benzonitrile(1097210-25-7)
• EPA Substance Registry System: (S)-4-(2-bromo-1-hydroxyethyl)benzonitrile(1097210-25-7)

Safety Data

• Hazardous Substances Data: 1097210-25-7(Hazardous Substances Data)

Upstream product

• 20099-89-2 4-Cyanophenacyl bromide 
• 85554-13-8 (±)-4-(2-bromo-1-hydroxyethyl)benzonitrile 

Downstream Products

• 1265323-48-5 ethyl (3S)-1-[(2S)-2-(4-cyanophenyl)-2-hydroxyethyl]piperidine-3-carboxylate 
• 1265323-51-0 (S)-ethyl 1-((S)-2-(tert-butyldimethylsilyloxy)-2-(4-cyanophenyl)ethyl)piperidine-3-carboxylate 
• 1265750-07-9 (S)-ethyl 1-((S)-2-(tert-butyldimethylsilyloxy)-2-(4-((Z)-N'-hydroxycarbamimidoyl)phenyl)ethyl)piperidine-3-carboxylate 
• 1304788-16-6 C₁₅H₁₃NO₂ 
• 1265323-36-1 2-((R)-1-((S)-2-(4-(5-(1-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidin-3-yl)acetic acid 
• 1265323-31-6 2-((R)-1-((S)-2-hydroxy-2-(4-(5-(4-phenyl-5-(trifluoromethyl)thiophen-2-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid 
• 1265323-61-2 ethyl 2-((R)-1-((S)-2-(tert-butyldimethylsilyloxy)-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetate 
• 1265750-10-4 ethyl 2-((R)-1-((S)-2-(tert-butyldimethylsilyloxy)-2-(4-((Z)-N'-hydroxycarbamimidoyl)phenyl)ethyl)piperidin-3-yl)acetate 
• 1265323-60-1 ethyl 2-((R)-1-((S)-2-(tert-butyldimethylsilyloxy)-2-(4-cyanophenyl)ethyl)piperidin-3-yl)acetate 
• 1265323-59-8 (S)-4-(2-bromo-1-(tert-butyldimethylsilyloxy)-ethyl)benzonitrile 
• 179694-33-8 (S)-(+)-2-(4-cyanophenyl)oxirane 

Relevant articles and documents

Selective Asymmetric Transfer Hydrogenation of α-Substituted Acetophenones with Bifunctional Oxo-Tethered Ruthenium(II) Catalysts

A practical method for the asymmetric transfer hydrogenation of α-substituted ketones was developed utilizing oxo-tethered N-sulfonyldiamine-ruthenium complexes. Reduction by HCO2H and HCO2K in a mixed solvent of EtOAc/H2O allowed for the selective synthesis of halohydrins from 2-bromoacetophenone (98%) and 2-chloroacetophenone (>99%), leading to suppressed undesired side reactions stemming from formylation under the typical reaction conditions using an azeotropic 5:2 mixture of HCO2H and Et3N. A range of functional groups, such as halogens, methoxy, nitro, dimethylamino, and ester groups, were well tolerated, highlighting the potential of this method. Nearly complete selectivity with a preferable ee was maintained even with a substrate/catalyst (S/C) ratio of 5000. This catalyst system was also effective for the asymmetric reduction of α-sulfonated ketones without eroding the leaving group. (Figure presented.).

SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS

Disclosed are compounds of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is formula (II) Q is a substituted 5-membered monocyclic heteroaryl group; W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS

Compounds of Formula (I) or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.